Brief: Merck Says Transaction Approved, Expected To Close In Second Half 2025
April 28 (Reuters) - Merck KGaA MRCG.DE: MERCK KGAA, DARMSTADT, GERMANY TO ACQUIRE SPRINGWORKS THERAPEUTICS TO ACCELERATE SUSTAINABLE GROWTH OF HEALTHCARE BUSINESS MERCK KGAA - TRANSACTION APPROVED, EXPECTED TO CLOSE IN SECOND HALF 2025 Source text: ID:nGNX5S1mxJ Further company coverage: MRCG.DE ((Reuters.Briefs@thomsonreuters.com;))
Recent news on SpringWorks Therapeutics
See all newsBrief: Merck KGaA Completes Acquisition Of Springworks Therapeutics
Brief: Springworks Therapeutics Expects Nirogacestat Decision From European Commission In Q3
Brief: EMA's CHMP Re-Examines Rejection Of Kisunla For Early Alzheimer’S Treatment
Brief: SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN
Brief: SpringWorks Therapeutics Receives Positive CHMP Opinion For Mirdametinib For The Treatment Of Adult And Pediatric Patients With NF1-PN